Neurofibromatoses Type I (Von Recklinghausen’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Neurofibromatoses Type I Pipeline Drugs Market Report Overview
Neurofibromatosis type 1 (NF1) is also called von Recklinghausen’s disease. It is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by a mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy, and radiation therapy.
The NF1 pipeline market research report provides comprehensive information on the therapeutics under development for NF1, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for NF1 and features dormant and discontinued projects.
NF1 Pipeline Products Market Segmentation by Targets
The key targets in the NF1 pipeline products market are Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Alkaline Phosphatase Tissue Nonspecific Isozyme, Cells Expressing Membrane Cofactor Protein, Cyclin-Dependent Kinase 4, Cyclin Dependent Kinase 6, and Cytotoxic T Lymphocyte Protein 4 among others. Dual Specificity Mitogen Activated Protein Kinase Kinase 1 is the leading target in the pipeline.
NF1 Pipeline Products Market Analysis by Targets
For more target insights into the NF1 pipeline products market, download a free report sample
NF1 Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the NF1 pipeline products market are Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Alkaline Phosphatase Tissue Nonspecific Isozyme Activator, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Cytotoxic To Cells Expressing Membrane Cofactor Protein among others. Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor is the leading MoA in the pipeline market.
NF1 Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the NF1 pipeline products market, download a free report sample
NF1 Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the NF1 pipeline products market are oral, intravenous, intraperitoneal, subcutaneous, intralesional, and intrapleural among others. Oral is the most preferred route for administration.
NF1 Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the NF1 pipeline products market, download a free report sample
NF1 Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the NF1 pipeline products market are small molecule, monoclonal antibody, biologic, gene therapy, and oncolytic virus. The leading molecule type is the small molecule.
NF1 Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the NF1 pipeline products market, download a free report sample
NF1 Pipeline Products Market - Competitive Landscape
Some of the leading companies in the NF1 pipeline products market are AstraZeneca Plc, Healx Ltd, Advenchen Laboratories LLC, Alexion Pharmaceuticals Inc, Binjiang Pharma, Inc., Bristol-Myers Squibb Co, Eli Lilly and Co, Fochon Pharmaceutical Ltd, and Mulberry Biotherapeutics Inc among others. AstraZeneca Plc is the leading company in the NF1 pipeline products market.
NF1 Pipeline Products Market Analysis by Companies
To know more about the leading players in the NF1 pipeline products market, download a free report sample
NF1 Pipeline Products Market Report Overview
| Key Targets | Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Alkaline Phosphatase Tissue Nonspecific Isozyme, Cells Expressing Membrane Cofactor Protein, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, and Cytotoxic T Lymphocyte Protein 4 |
| Key Mechanisms of Action | Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Alkaline Phosphatase Tissue Nonspecific Isozyme Activator, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Cytotoxic To Cells Expressing Membrane Cofactor Protein |
| Key Routes of Administration | Oral, Intravenous, Intraperitoneal, Subcutaneous, Intralesional, and Intrapleural |
| Key Molecule Type | Small Molecule, Monoclonal Antibody, Biologic, Gene Therapy, and Oncolytic Virus |
| Leading Companies | AstraZeneca Plc, Healx Ltd, Advenchen Laboratories LLC, Alexion Pharmaceuticals Inc, Binjiang Pharma, Inc., Bristol-Myers Squibb Co, Eli Lilly and Co, Fochon Pharmaceutical Ltd, and Mulberry Biotherapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of NF1.
- The pipeline guide reviews pipeline therapeutics for NF1 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in NF1 therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates NF1 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for NF1 (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for NF1.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the NF1 pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Alexion Pharmaceuticals Inc
AstraZeneca Plc
Binjiang Pharma, Inc.
Bristol-Myers Squibb Co
Eli Lilly and Co
Fochon Pharmaceutical Ltd
Healx Ltd
Mulberry Biotherapeutics Inc
NFlection Therapeutics Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Pasithea Therapeutics Corp
Pfizer Inc
Sino Biopharmaceutical Ltd
SpringWorks Therapeutics Inc
Vyriad Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the NF1 pipeline products market?
The key targets in the NF1 pipeline products market are Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Alkaline Phosphatase Tissue Nonspecific Isozyme, Cells Expressing Membrane Cofactor Protein, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, and Cytotoxic T Lymphocyte Protein 4.
-
What are the key mechanisms of action in the NF1 pipeline products market?
The key mechanisms of action in the NF1 pipeline products market are Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Alkaline Phosphatase Tissue Nonspecific Isozyme Activator, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, and Cytotoxic To Cells Expressing Membrane Cofactor Protein.
-
What are the key routes of administration in the NF1 pipeline products market?
The key routes of administration in the NF1 pipeline products market are oral, intravenous, intraperitoneal, subcutaneous, intralesional, and intrapleural.
-
What are the key molecule types in the NF1 pipeline products market?
The key molecule types in the NF1 pipeline products market are small molecule, monoclonal antibody, biologic, gene therapy, and oncolytic virus.
-
Which are the leading companies in the NF1 pipeline products market?
Some of the leading companies in the NF1 pipeline products market are AstraZeneca Plc, Healx Ltd, Advenchen Laboratories LLC, Alexion Pharmaceuticals Inc, Binjiang Pharma, Inc., Bristol-Myers Squibb Co, Eli Lilly and Co, Fochon Pharmaceutical Ltd, and Mulberry Biotherapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports